SOURCE: Market Pulse

September 18, 2006 08:55 ET

Market Pulse Breaking News Alert for Monday, Sept. 18, 2006: BIEL -- BioElectronics' ActiPatch Featured in BioMechanics Article!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- September 18, 2006 -- Market Pulse News Alert for this AM, Stocks to Watch are: BioElectronics Corporation (PINKSHEETS: BIEL), Cisco Systems, Inc. (NASDAQ: CSCO), Genta Inc. (NASDAQ: GNTA) and Microsoft Corp. (NASDAQ: MSFT).

Investors need to be watching BioElectronics Corporation (PINKSHEETS: BIEL) this AM! BioElectronics is the developer and marketer of advanced, inexpensive, disposable, drug-free, medical devices, under the trade name ActiPatch Therapy, which are cleared by the U.S. FDA, the European Union and the Canadian regulatory authorities. ActiPatch™ is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method designed to reduce swelling, relieve pain and enhance healing of surgical incisions, chronic wounds and orthopedic conditions. The company most recently signed a major distribution agreement with OrthoPro LLC for distribution of the ActiPatch™ product. BIEL also recently signed an agreement with Adams BioMedical, Inc., Bremerton, Washington, to establish a national network of independent sales agents and distributors in the podiatry, orthotics and prosthesis markets. More corporate milestones include a sales and distribution agreement with Mentor Corp. for worldwide distribution in plastic surgery and the signing of a retail distribution agreement with Profoot, Inc., a major retail foot care manufacturer, distributor, and Wal-Mart's Vendor of the Year, to internationally market and sell a retail foot care product line. BIEL is developing new products for repetitive stress injuries, such as heel pain, carpel tunnel, back pain, sprains and strains and chronic wounds. BioElectronics has also entered into the sports medicine markets addressing the needs of professional athletes. BIEL has established the use of ActiPatch™ by a number of professional sports teams. The company boasts five unique orthopedic designs aimed at working in conjunction with other therapies team trainers and physicians already provide. BioElectronics is emerging from a development stage company and is ready to capitalize on the potential market for effective therapies which is estimated at $6.5 billion in the U.S. and over $20 billion worldwide. BIEL is poised to become a significant player in the medical devices industry. BIEL just had excellent news out in a press release before today's opening bell announcing today that the September issue of the influential newsletter, BioMechanics features an article by Michael Z. Metzger, DPM, MBA! This could be great news for investors!

BioElectronics Corporation (PINKSHEETS: BIEL) announced today that the September issue of the influential newsletter, BioMechanics features an article by Michael Z. Metzger, DPM, MBA. Dr. Michael Z. Metzger is the founder of Innovative Healthcare Resources based in Houston. The article, "Miniaturization Prompts Reconsideration of PEMF Therapy," Suggests a host of new applications for the BioElectronic's ActiPatch device.

Dr. Metzger's article discusses the effectiveness of BioElectronics Corporation's ActiPatch in comparison to the older and much larger pulsed electromagnetic field therapy (PEMF) equipment that has been used for decades. ActiPatch is an FDA-cleared, drug free, anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for a breakthrough price.

In the article Dr. Metzger wrote, "Research conducted at a leading College of Medicine has concluded that ActiPatch provides an adequate dose of electromagnetic energy to treat soft tissue injuries. Additionally the cumulative effect of continuous delivery provides greater therapeutic benefit than the intermittent and inconvenient doses available with stationary devices." Dr. Metzger's conclusion was that "practitioners now have the option of treating an ever-widening assortment of acute and chronic inflammatory conditions with ActiPatch."

Dr. Metzger's article also suggests investigation of several categories of injury not previously considered for PEMF treatment such as; postoperative therapy, ankle sprains, plantar fasciitis, wounds, and pain management. In conclusion, Dr. Metzger suggests that research in the areas of musculoskeletal injuries and diseases and wound healing could hold promising additional applications for this therapy.

"Dr. Metzger wrote that medical braces, supports and bandages will be transformed into a Therapeutic Brace© or Therapeutic Bandage© embedded with the pain relief and recuperative benefits of this very inexpensive, proven therapy," said Andrew Whelan, President of BioElectronics.

To view the article, "Miniaturization prompts reconsideration of PEMF therapy" in BioMechanics visit: For more information on BioElectronics Corporation visit

Stocks in the news and acting well as of late include: Cisco Systems, Inc. (NASDAQ: CSCO), Genta Inc. (NASDAQ: GNTA) and Microsoft Corp. (NASDAQ: MSFT).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties, disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated in free trading shares of common stock, available for public trading as follows: BioElectronics Corporation compensation from a third party shareholder: five hundred thousand free trading shares of stock in BioElectronics Corporation, already received from a third party shareholder. MP has also been compensated two hundred thousand restricted shares of BioElectronics Corporation by the company. To date, MP has sold two hundred thousand shares of stock in BioElectronics Corporation for proceeds totaling seventy three thousand three hundred dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information